Skip to main content
Erschienen in: AIDS and Behavior 11/2018

12.05.2018 | Original Paper

The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men

verfasst von: Megha L. Mehrotra, K. Rivet Amico, Vanessa McMahan, David V. Glidden, Patricia Defechereux, Juan V. Guanira, Robert M. Grant

Erschienen in: AIDS and Behavior | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Qualitative studies suggest that social relationships play an important role in HIV pre-exposure prophylaxis (PrEP) use, but there have been few quantitative assessments of the role of social relationships in PrEP uptake or adherence. We examined the association between disclosure of study participation or LGBT identity and PrEP use in the 1603 HIV-negative participants enrolled in the iPrEx OLE study. We also evaluated the association between LGBT social group involvement and PrEP use. Study participation disclosure to parents and LGBT identity disclosure to anyone in a participant’s social network were associated with greater PrEP uptake. Study participation disclosure to partners was associated with higher probability of having protective PrEP drug concentrations compared [risk difference 0.15 95% CI (0.01, 0.30)]. For each additional type of LGBT organization a participant was involved in, the probability of PrEP uptake and having protective drug concentrations increased by 0.04 [95% CI (0.03, 0.06)] and 0.04 (95% CI (0.02, 0.07)] respectively. Overall, social context was associated with PrEP use in iPrEx OLE, and should be taken into consideration when designing future PrEP implementation programs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hankins C, Macklin R, Warren M. Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access. J Int AIDS Soc. 2015;18:3.CrossRef Hankins C, Macklin R, Warren M. Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access. J Int AIDS Soc. 2015;18:3.CrossRef
2.
Zurück zum Zitat Eaton LA, Kalichman S. Translating Pre-Exposure Prophylaxis Evidence into Practice and Public Health Impact. In: Advances Biomedical, editor. Biomedical advances in HIV prevention: social and behavioral perspectives. New York: Springer Science & Business Media; 2013. Eaton LA, Kalichman S. Translating Pre-Exposure Prophylaxis Evidence into Practice and Public Health Impact. In: Advances Biomedical, editor. Biomedical advances in HIV prevention: social and behavioral perspectives. New York: Springer Science & Business Media; 2013.
3.
Zurück zum Zitat Sorensen G, et al. Model for incorporating social context in health behavior interventions: applications for cancer prevention for working-class, multiethnic populations. Prev Med. 2003;37:188–97.CrossRef Sorensen G, et al. Model for incorporating social context in health behavior interventions: applications for cancer prevention for working-class, multiethnic populations. Prev Med. 2003;37:188–97.CrossRef
4.
Zurück zum Zitat Berkman LF, Syme SL. Social networks, host resistance, and mortality: A nine-year follow-up study of Alameda County residents. Am J Epidemiol. 1979;109:186–204.CrossRef Berkman LF, Syme SL. Social networks, host resistance, and mortality: A nine-year follow-up study of Alameda County residents. Am J Epidemiol. 1979;109:186–204.CrossRef
5.
Zurück zum Zitat Cohen S. Social relationships and health. Am Psychol. 2004;59:676–84.CrossRef Cohen S. Social relationships and health. Am Psychol. 2004;59:676–84.CrossRef
6.
Zurück zum Zitat Uchino BN. Social support and health: a review of physiological processes potentially underlying links to disease outcomes. J Behav Med. 2006;29:377–87.CrossRef Uchino BN. Social support and health: a review of physiological processes potentially underlying links to disease outcomes. J Behav Med. 2006;29:377–87.CrossRef
7.
Zurück zum Zitat Gottlieb BH, Bergen AE. Social support concepts and measures. J Psychosom Res. 2010;69:511–20.CrossRef Gottlieb BH, Bergen AE. Social support concepts and measures. J Psychosom Res. 2010;69:511–20.CrossRef
8.
Zurück zum Zitat Kumar S, Calvo R, Avendano M, Sivaramakrishnan K, Berkman LF. Social support, volunteering and health around the world: cross-national evidence from 139 countries. Soc Sci Med. 2012;1982(74):696–706.CrossRef Kumar S, Calvo R, Avendano M, Sivaramakrishnan K, Berkman LF. Social support, volunteering and health around the world: cross-national evidence from 139 countries. Soc Sci Med. 2012;1982(74):696–706.CrossRef
9.
Zurück zum Zitat DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 2004;23:207–18.CrossRef DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 2004;23:207–18.CrossRef
10.
Zurück zum Zitat Ware NC, et al. What’s love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis (PrEP) for HIV serodiscordant couples. J Acquir Immune Defic Syndr. 2012;1999:59. Ware NC, et al. What’s love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis (PrEP) for HIV serodiscordant couples. J Acquir Immune Defic Syndr. 2012;1999:59.
11.
Zurück zum Zitat Liu A, et al. Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr. 2014;1999(67):528–37.CrossRef Liu A, et al. Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr. 2014;1999(67):528–37.CrossRef
12.
Zurück zum Zitat Donnell D, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;1999(66):340–8.CrossRef Donnell D, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;1999(66):340–8.CrossRef
13.
Zurück zum Zitat Haberer JE, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10:e1001511.CrossRef Haberer JE, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10:e1001511.CrossRef
14.
Zurück zum Zitat Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr. 2013;1999(63 Suppl 2):S122–9.CrossRef Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr. 2013;1999(63 Suppl 2):S122–9.CrossRef
15.
Zurück zum Zitat Grant RM, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820–9.CrossRef Grant RM, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820–9.CrossRef
16.
Zurück zum Zitat Amico KR, et al. Experiences with HPTN 067/ADAPT study-provided open-label PrEP among women in cape town: facilitators and barriers within a mutuality framework. AIDS Behav. 2017;21:1361–75.CrossRef Amico KR, et al. Experiences with HPTN 067/ADAPT study-provided open-label PrEP among women in cape town: facilitators and barriers within a mutuality framework. AIDS Behav. 2017;21:1361–75.CrossRef
17.
Zurück zum Zitat Gilmore HJ, et al. Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco. AIDS Patient Care STDs. 2013;27:560–6.CrossRef Gilmore HJ, et al. Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco. AIDS Patient Care STDs. 2013;27:560–6.CrossRef
18.
Zurück zum Zitat Arnold T, et al. Social, structural, behavioral and clinical factors influencing retention in Pre-Exposure Prophylaxis (PrEP) care in Mississippi. PLoS ONE. 2017;12:e0172354.CrossRef Arnold T, et al. Social, structural, behavioral and clinical factors influencing retention in Pre-Exposure Prophylaxis (PrEP) care in Mississippi. PLoS ONE. 2017;12:e0172354.CrossRef
19.
Zurück zum Zitat Goicochea, P. Barriers and facilitators to PrEP adherence in iPrEx: a prevention trial that started in 3 Andean cities. (2009). Goicochea, P. Barriers and facilitators to PrEP adherence in iPrEx: a prevention trial that started in 3 Andean cities. (2009).
20.
Zurück zum Zitat Berkman LF, Glass T, Brissette I, Seeman TE. From social integration to health: Durkheim in the new millennium☆☆This paper is adapted from Berkman LF, Glass T. Social integration, social networks, social support and health. In Berkman LF, Kawachi I, Social Epidemiology. New York: Oxford University Press; and Brissette I, Cohen S, Seeman T. Measuring social integration and social networks. In Cohen S, Underwood L, Gottlieb B, Social Support Measurements and Intervention. New York: Oxford University Press. Soc Sci Med 51: 843–857 (2000). Berkman LF, Glass T, Brissette I, Seeman TE. From social integration to health: Durkheim in the new millennium☆☆This paper is adapted from Berkman LF, Glass T. Social integration, social networks, social support and health. In Berkman LF, Kawachi I, Social Epidemiology. New York: Oxford University Press; and Brissette I, Cohen S, Seeman T. Measuring social integration and social networks. In Cohen S, Underwood L, Gottlieb B, Social Support Measurements and Intervention. New York: Oxford University Press. Soc Sci Med 51: 843–857 (2000).
21.
Zurück zum Zitat Grant RM, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.CrossRef Grant RM, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.CrossRef
22.
Zurück zum Zitat Hosek SG, et al. The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr. 2013;1999(62):447–56.CrossRef Hosek SG, et al. The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr. 2013;1999(62):447–56.CrossRef
23.
Zurück zum Zitat Grohskopf LA, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013;1999(64):79–86.CrossRef Grohskopf LA, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013;1999(64):79–86.CrossRef
24.
Zurück zum Zitat Castillo-Mancilla J, et al. Emtricitabine-triphosphate in dried blood spots as a marker of recent dosing. Antimicrob Agents Chemother. 2016;60:6692–7.CrossRef Castillo-Mancilla J, et al. Emtricitabine-triphosphate in dried blood spots as a marker of recent dosing. Antimicrob Agents Chemother. 2016;60:6692–7.CrossRef
25.
Zurück zum Zitat Anderson PL, et al. Emtricitabine–Tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4:151.CrossRef Anderson PL, et al. Emtricitabine–Tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4:151.CrossRef
27.
Zurück zum Zitat Localio AR, Margolis DJ, Berlin JA. Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression. J Clin Epidemiol. 2007;60:874–82.CrossRef Localio AR, Margolis DJ, Berlin JA. Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression. J Clin Epidemiol. 2007;60:874–82.CrossRef
28.
Zurück zum Zitat Williams R. Using the margins command to estimate and interpret adjusted predictions and marginal effects. Stata J. 2012;12:308–31. Williams R. Using the margins command to estimate and interpret adjusted predictions and marginal effects. Stata J. 2012;12:308–31.
29.
Zurück zum Zitat STATA Statistical Software: Release 13. (StataCorp LP). STATA Statistical Software: Release 13. (StataCorp LP).
30.
Zurück zum Zitat Tangmunkongvorakul A, et al. Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care. 2013;25:961–7.CrossRef Tangmunkongvorakul A, et al. Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care. 2013;25:961–7.CrossRef
31.
Zurück zum Zitat Galea JT, et al. Acceptability of Pre-Exposure Prophylaxis (PrEP) as an HIV prevention strategy: barriers and facilitators to PrEP uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22:256–62.CrossRef Galea JT, et al. Acceptability of Pre-Exposure Prophylaxis (PrEP) as an HIV prevention strategy: barriers and facilitators to PrEP uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22:256–62.CrossRef
Metadaten
Titel
The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men
verfasst von
Megha L. Mehrotra
K. Rivet Amico
Vanessa McMahan
David V. Glidden
Patricia Defechereux
Juan V. Guanira
Robert M. Grant
Publikationsdatum
12.05.2018
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 11/2018
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-018-2151-0

Weitere Artikel der Ausgabe 11/2018

AIDS and Behavior 11/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.